JA Solar Holdings Co., Ltd. (NASDAQ:JASO), a major China solar company trading an average of 2.6 million shares daily on the NYSE, reported fourth quarter and year ending results on Monday showing net income of $23 million in the fourth quarter compared to a net loss of $37 million in the third. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) shares after opening at $12.82 moved to $13.14 on last trade day and at the end of the day closed at $11.66. Company price to sales ratio in past twelve months was calculated as 0.08 and price to cash ratio as 0.29. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) showed a positive weekly performance of 4.39%.
U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) declared its fourth quarter earnings on Thursday. The company posted a net loss of 4 cents per share, which is $1.3 million in the reported quarter, which showed a wide improvement from its previous year’s same quarter net loss of 99 cents per share or $30.8 million. U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) shares advanced 8.36% in last trading session and ended the day on $3.24. PRTS return on equity ratio is recorded as -177.60% and its return on assets is -57.90%. U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) yearly performance is 155.12%.
Shares of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage bio- pharmaceutical company focused on developing protein therapeutics to fight cancer and other inflammatory diseases, jumped as much as 22% after announcing a collaborative dealwith Bristol-Myers Squibb (NYSE: BMY ) before the opening bell. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shares moved up 22.61% in last trading session and was closed at $22.99, while trading in range of $20.63 – $23.08. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) year to date (YTD) performance is 36.93%.
Rosetta Genomics Ltd. (NASDAQ:ROSG), which is a microRNA-based molecular diagnostics maker and supplier, has reportedly drawn out its plans to advance in its MicroRNA platform technologies in diagnostics as well as therapeutics. The company is set to get ahead with an aggressive plan to introduce one product each year right from 2015. The company’s ambitious plans have drawn attention of the analyst at the Zacks Small Cap research firm, as the research from has now set the price target of the company to $10.50. Rosetta Genomics, Ltd. (NASDAQ:ROSG) weekly performance is 1.80%. On last trading day company shares ended up $6.22. Rosetta Genomics, Ltd. (NASDAQ:ROSG) distance from 50-day simple moving average (SMA50) is 55.58%. Analysts mean target price for the company is $3.50.